In terms of efficacy, brigatinib has been shown to exhibit clinical efficacy in patients with ALK+ NSCLC refractory to crizotinib (objective response rate [ORR], 45-56% and PFS, 16.7 months). This evidence concerns the gene ALK and non-small cell lung carcinoma.